CytomX Therapeutics Inc (CTMX) — Cash Flow Reinvestment Rate

Latest as of March 2023: 15.69x

CytomX Therapeutics Inc (CTMX) has a Cash Flow Reinvestment Rate of 15.69x as of March 2023, reinvesting $146.64 Million (capex $48.00K plus investments $-146.59 Million) from operating cash flow of $9.35 Million. See CTMX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

15.69x
(Capex + Investments) / Operating CF

Total Reinvested

$146.64 Million
Capex + Investments

Operating Cash Flow

$9.35 Million
USD

Capital Expenditures

$48.00K
USD

CytomX Therapeutics Inc Cash Flow Reinvestment Rate (2014–2020)

Historical reinvestment intensity for CytomX Therapeutics Inc across 3 annual periods. For the full cash flow conversion analysis, see CytomX Therapeutics Inc operating cash flow efficiency.

Annual Cash Flow Reinvestment Rate for CytomX Therapeutics Inc (2014–2020)

Year-by-year capital reinvestment analysis for CytomX Therapeutics Inc. See CTMX financial flexibility score to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2020 3.56x $18.72 Million $5.26 Million $2.31 Million ▲ +393.7%
2017 0.72x $122.83 Million $170.37 Million $1.56 Million ▼ -82.3%
2014 4.08x $129.81 Million $31.80 Million $1.66 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow